Studying the effect of spironolactone treatment on right ventricular function in patients with pulmonary hypertension group 1

Abstract

Abstract

Objectives

Despite the evidence showing the effect of vasoactive hormones including aldosterone in the pathophysiology of pulmonary arterial hypertension (PAH), few clinical reports are available about the effect of treating PAH with aldosterone antagonists, so in this study, the effect of treating patients with idiopathic PAH with the drug Aldosterone inhibitor spironolactone was discussed.

Methodology

This study was conducted as a randomized clinical trial with a double-blind control group. All patients diagnosed with PAH referred to Imam Reza (AS) hospital in Mashhad from the beginning of August 2015 to the beginning of August 2016 were included in this study. The patients were randomly treated with the standard treatment of tadalafil 10-20 mg once a day plus bozentan 125 mg, once or twice a day or standard treatment plus spironolactone (25 mg) daily for three months. Before the start and after three months, the patients were evaluated. After collecting the data, they were analyzed using SPSS version 16 software, and p>0.05 was considered as a significant level.

Results

Routine treatment in the control group and routine treatment plus spironolactone in the intervention group had little effect on the severity of dilatation of the patients participating in the study but it had significant effect on TAPSE.

Conclusion

After the intervention a significant increase in the TAPSE index was observed compared to the control group. Significant difference in other echocardiographic and clinical indicators examined after the intervention in the intervention groups and the witness was not identified.